Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature
- PMID: 32489723
- PMCID: PMC7255540
- DOI: 10.7759/cureus.7868
Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature
Abstract
Postural orthostatic tachycardia syndrome (POTS) is an autonomic disorder characterized by symptoms such as palpitations, dyspnea, chest discomfort, and lightheadedness affecting various systems. The pathophysiology of POTS is not completely understood due to a variety of symptoms showing that the disease is multifactorial. There is no approved uniform management strategy for POTS and hence, no drug has been approved by the United States (US) Food and Drug Administration (FDA) for it. Ivabradine is an FDA-approved drug for stable symptomatic heart failure (HF) and patients with an ejection fraction (EF) of ≤35%. Previous studies have depicted improvement in symptoms of POTS with the use of ivabradine. It is a selective inhibitor of funny sodium channels (If) in the sinoatrial (SA) node cells resulting in the prolongation of the slow diastolic depolarization (phase IV) and reduction in the heart rate (HR). Although beta-adrenoceptor blockers are commonly used to lower HR in patients with POTS, they are less ideal due to numerous adverse effects. This review aims to provide a comprehensive and up-to-date picture of all the studies and case reports that utilized ivabradine for the treatment of POTS along with a precise overview of epidemiology, pathophysiology, and types of POTS. To conclude, we recommend further research on the effectiveness of ivabradine in patients who experience symptoms of POTS. Other than stable chronic angina pectoris, its application in this setting has been proven to be effective and safe. Further evaluation by means of randomized control trials is required to encourage use of this HR-lowering agent in common disorders other than HF and stable angina, i.e. POTS.
Keywords: autoimmune pots; deconditioning pots; heart rate-lowering drug; hyperadrenergic pots; hypovolemic pots; ivabradine; neuropathic pots; postural orthostatic tachycardia syndrome; postural tachycardia syndrome; pots.
Copyright © 2020, Tahir et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine Therapy.Cardiol Rev. 2024 May-Jun 01;32(3):279-284. doi: 10.1097/CRD.0000000000000503. Epub 2022 Dec 5. Cardiol Rev. 2024. PMID: 36729924
-
Pathophysiology and management of postural orthostatic tachycardia syndrome (POTS): A literature review.Curr Probl Cardiol. 2025 Mar;50(3):102977. doi: 10.1016/j.cpcardiol.2024.102977. Epub 2024 Dec 18. Curr Probl Cardiol. 2025. PMID: 39706392 Review.
-
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.J Am Coll Cardiol. 2021 Feb 23;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029. J Am Coll Cardiol. 2021. PMID: 33602468 Clinical Trial.
-
Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience.Pacing Clin Electrophysiol. 2017 Nov;40(11):1242-1245. doi: 10.1111/pace.13182. Epub 2017 Sep 20. Pacing Clin Electrophysiol. 2017. PMID: 28846151
-
Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies.Annu Rev Med. 2020 Jan 27;71:235-248. doi: 10.1146/annurev-med-041818-011630. Epub 2019 Aug 14. Annu Rev Med. 2020. PMID: 31412221 Review.
Cited by
-
Recent updates on novel therapeutic targets of cardiovascular diseases.Mol Cell Biochem. 2021 Jan;476(1):145-155. doi: 10.1007/s11010-020-03891-8. Epub 2020 Aug 26. Mol Cell Biochem. 2021. PMID: 32845435 Review.
-
Suspected Diphtheria Toxoid and Tetanus Toxoid (dTdap) Booster Vaccine-Induced Postural Orthostatic Tachycardia Syndrome (POTS).Cureus. 2024 Jul 7;16(7):e64008. doi: 10.7759/cureus.64008. eCollection 2024 Jul. Cureus. 2024. PMID: 39109119 Free PMC article.
-
Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review.BMC Cardiovasc Disord. 2024 Nov 13;24(1):643. doi: 10.1186/s12872-024-04315-x. BMC Cardiovasc Disord. 2024. PMID: 39538129 Free PMC article.
-
Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.Microorganisms. 2023 Sep 12;11(9):2301. doi: 10.3390/microorganisms11092301. Microorganisms. 2023. PMID: 37764145 Free PMC article.
-
Case report of long-term postural tachycardia syndrome in a patient after messenger RNA coronavirus disease-19 vaccination with mRNA-1273.Eur Heart J Case Rep. 2023 Aug 19;7(8):ytad390. doi: 10.1093/ehjcr/ytad390. eCollection 2023 Aug. Eur Heart J Case Rep. 2023. PMID: 37650075 Free PMC article.
References
-
- On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. Da Costa JM. Am J Med Sci. 1951;11:559–567.
-
- Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Schondorf R, Low PA. Neurology. 1993;43:132–137. - PubMed
-
- Postural orthostatic tachycardia syndrome: prevalence, pathophysiology, and management. Zadourian A, Doherty TA, Swiatkiewicz I, Taub PR. Drugs. 2018;78:983–994. - PubMed
-
- Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. Fedorowski A. J Intern Med. 2019;285:352–366. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous